Significant progresses have been made through CRISPR-Cas genome editing and antisense oligonucleotide (ASO) therapies in many polyQ diseases, especially in HD, SCA2, and SCA3 [27–38]. The gene discussed is ATXN3; the disease is Huntington disease.